Every provider we've read

A cash-pay platform listing GLP-1s, sermorelin, NAD+ and enclomiphene, with clinical visits and shipping included in its cited auto-refill offers.

A broad prescription platform with public GLP-1 offers, conflicting renewal guidance and a BPC-157 listing outside the recommendations.

An app-based prescription platform spanning GLP-1, menopause and longevity care, with long-plan headlines and product-specific terms.

A longevity-focused prescription platform with several formulations, prepaid introductions and separate membership-plus-drug programs.

Compounded GLP-1 bundles with published monthly prices, restrictive refund terms and conflicting cancellation deadlines.

A physician-founded longevity shop with a listed price for rapamycin, NAD+ and GLP-1s, on a site still being rebuilt.

A broad prescription catalog with bundled service prices, advance protocol shipments and a substantial cancellation commitment.

Dose-flat GLP-1 offers and a detailed care menu, with prepaid-plan and order-cancellation conditions worth reading before checkout.

A public prescription shop with dose-specific purchase prices, stated monitoring plans and an unconfirmed recurring payment schedule.

Several longevity formulations and plan choices, with variable renewal timing and conflicting cancellation instructions to resolve before checkout.

A no-membership menu of GLP-1s, NAD+ and sermorelin for people who train, held back by one unclear pharmacy on its list.

A cash-pay menu of NAD+, sermorelin, glutathione, GLP-1s and men's TRT, with no membership fee and public prices for most of it.

Dose-flat compounded GLP-1 offers with an annual membership, messaging support and a possible extra prescription-transmission fee.

Compounded GLP-1 care with public starting prices, a flat-dose claim and refund and renewal terms that need a careful comparison.

A lab-led hormone and weight-care practice with individualized costs, extended consultations and inconsistent published laboratory refund terms.

One-time GLP-1 offers and commercially manufactured testosterone programs, with broader subscription and laboratory terms to reconcile.

A broad prescription catalog with separately priced membership and unresolved GLP-1 fee wording that needs a written total.

A peptide-led men's program with needle-free sermorelin, NAD+ and glutathione, held back because it doesn't say which Strive site fills orders.

A membership and one-time prescription shop with separate visit and shipping costs, plus unresolved regulatory questions across its peptide catalog.

A clinician-reviewed care platform with starting prices tied to selected plan lengths, separate denial fees and incomplete public cancellation terms.

A bundled compounded-care platform with named clinical and pharmacy partners, strict refund terms and quotes that need a renewal schedule.

A lab-first program with live consultation and explicit four-week billing, plus differing public pharmacy lists to clarify.

A weight-care program with public plan tables, fixed four-week billing and product-specific state access that still needs confirmation.

A broad treatment and coaching menu, with quarterly longevity offers and important limits on price locks, TRT fees and refunds.

A broad Altro-hosted treatment catalog with explicit twenty-eight-day charges, treatment-specific lab requirements and strict order-stage refunds.

A lab-first primary care membership that prescribes only branded GLP-1s and FDA-approved hormones, with the drug billed by the pharmacy.

A broad prescription catalog with explicit renewal examples, payment before medical review and product-specific shipping and refund limits.

A device-and-app weight-care program with introductory marketing, prepaid renewal terms and clinical-network disclosures to reconcile.

A broad prescription menu with manual-refill descriptions, program-specific fees and inconsistent hormone-visit and cancellation wording.

Protocol-based GLP-1, NAD+ and glutathione care with an unresolved ineligibility refund rule and a restricted-peptide menu.

A broad compounded-care catalog with visible plan choices, but renewal cadence and refund terms need a written reconciliation.

Prescription bundles with explicit four-week prices for selected products and important early-processing and refund conditions.

A men’s telehealth platform with a TRT testing offer, dissolving semaglutide tablets and billing and laboratory scope to confirm.

A compounded GLP-1 service with published plan ladders, but early renewal charges and conflicting prepaid-refund terms need clarification.

A cash-pay GLP-1 program offering shots and tablets; current public price fields require a written quote before comparison.

A broad prescription menu with no advertised monthly membership; current product quotes, refill timing and pharmacy assignment still need confirmation.

Texas and Florida care with separate membership and medication charges, but conflicting clinical-review refund promises.

Online prescription access with a current monthly NAD+ offer, longer GLP-1 commitments and an unresolved tesamorelin formulation.

A no-membership menu of NAD+, sermorelin, GHK-Cu cream and hormones, with a renewal notice each month instead of automatic charges.

A men’s health and longevity platform with public purchase options, strict renewal rules and pharmacy identity and discipline history to clarify.

Published GLP-1 and longevity plans with separate maintenance offers, treatment-specific testing and consultation deductions on eligible refunds.

A broad telehealth catalog with explicit four-week GLP-1 charges, public plan ladders and separate hormone-care requirements.

Compounded GLP-1s, NAD+ and sermorelin with printed plans, but inclusive-price claims differ from separate-fee terms.

Compounded GLP-1s, NAD+ and sermorelin with no separate membership advertised; confirm the full selected term and cancellation cutoff before paying.

GLP-1 formulations and a monthly sermorelin kit, with early renewal processing and refund conditions that need attention.

A GLP-1-only program with one price at every dose, four named pharmacies and strict billing rules and a limited medical-disqualification refund.

GLP-1 and NAD+ programs with a detailed refund policy, but conflicting billing descriptions and order-stage deadlines to reconcile.

Several injectable and needle-free longevity options with a named pharmacy partner, but unresolved product-price and renewal details.

A broad cash-pay treatment menu with published physician profiles, a mandatory processing fee and conflicting order-stage refund wording.

A compounded semaglutide and tirzepatide program with a full plan table, one price at every dose and a six-month money-back promise.

A GLP-1 care platform with public initial and follow-up package figures that differ from its homepage starting offers.

A women-focused care service with named clinical and pharmacy organizations, dose-flat GLP-1 offers and selected-plan costs to clarify.

A compounded GLP-1 program whose pricing page and terms disagree about the renewal interval, with a conditional weight-loss guarantee.

Provider-guided GLP-1 and longevity care with included consultation, but conflicting product prices and an unconfirmed renewal schedule.

Physician-guided GLP-1 and NAD+ programs with visible starting prices, dose-dependent fee terms and pharmacy-stage cancellation limits.

A menopause-focused messaging service with compounded and approved product options, fixed four-week billing and a short order-cancellation window.